Opinion|Videos|July 16, 2024
Navigating Biosimilar Uptake in New Patients
The panel discuss if including biosimilars on formulary at parity is enough to support their adoption.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do you direct new-start patients to a biosimilar? What about switching?
- Payers require generic medications over brand name in most instances. Why isn’t this the case for biosimilars?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Texas Hospitals Lose $27 Million a Day in Medicaid Funding Dispute
2
Bringing CAR T-Cell Therapy Into Community Cancer Centers
3
The True Cost of Running a Community CAR T-Cell Program
4
Higher Weight-Adjusted Waist Index Tied to CKD Mortality, Study Finds
5